Short answer
Xeris Biopharma Holdings, Inc. (XERS) filed an 8-K current report with the SEC on October 14, 2026 reporting Item 8.01 (Other Events). Xeris filed two patent infringement lawsuits against generic dichlorphenamide manufacturers and specialty pharmacies.
Xeris Biopharma Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Xeris filed two patent infringement lawsuits against generic dichlorphenamide manufacturers and specialty pharmacies
- Litigation follows grant of U.S. Patent No. 12,758,502 covering KEVEYIS®, supporting protection against generic competition
- Requested injunctions could delay or prevent defendants’ generic product launches
- Monetary damages, enhanced damages, attorneys’ fees, and costs sought, creating potential financial upside if successful
- Outcome remains uncertain, with litigation introducing legal costs and potential KEVEYIS® market disruption
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xeris Biopharma Holdings, Inc. 8-K filings
Get the next XERS 8-K as it lands
Follow XERS for push alerts, or ask the research agent what this filing means.